Biological Skin Substitutes Market Size, Share & Trends Analysis Report By Type (Human Donor Tissue-derived Products, Acellular Animal-derived Products), By Application (Acute Wound, Chronic Wound), By End-use, By Region, And Segment Forecasts, 2025 - 203

Biological Skin Substitutes Market Size, Share & Trends Analysis Report By Type (Human Donor Tissue-derived Products, Acellular Animal-derived Products), By Application (Acute Wound, Chronic Wound), By End-use, By Region, And Segment Forecasts, 2025 - 2030


Biological Skin Substitutes Market Growth & Trends

The global biological skin substitutes market size is expected to reach USD 579.08 million by 2030 and is expected to expand at a CAGR of 8.88% from 2025 to 2030 based on a new report by Grand View Research, Inc. The increasing prevalence of skin diseases, rising incidence of chronic diseases & trauma emergencies, and increasing consciousness regarding tissue engineering, along with potential pipeline products, are some of the major factors responsible for the growth of tissue nano transfection technology. Furthermore, increasing government and private organizations’ investment in research and development activities is likely to boost the demand for biological skin substitutes.

The COVID-19 pandemic has affected several aspects of the wound care process, which includes compliance with wound care visits, triggering alternative approaches such as the use of virtual care platforms or telemedicine and streaming videos on the social media platform to assist the patients with wound dressing and empowering a do-it-yourself wound dressing approach. There is an increasing desire to understand how the social dimensions of health impact the Quality of Life (QoL) and effectiveness of wound care patients. The direct consequence of such changes in health care is the disruption of the continuity of wound care in several ways. However, these changes have negatively impacted wound outcomes but also have driven the development of a virtual-based approach for patient visits.

The key companies in the market are attempting to improve their portfolio by upgrading their products, employing significant cooperative efforts, and considering acquisitions and government permissions to increase their client base and capture a larger share of the biological skin substitutes market.

Biological Skin Substitutes Market Report Highlights
  • Based on type, the human donor tissue-derived products segment accounted for the largest market share of 67.42% in 2024 as it allows better integration and acceptance by the patient's body
  • Based on application, the chronic wounds segment is expected to witness the fastest growth, with a CAGR of 9.13% over the forecast period due to the increasing prevalence of chronic wounds
  • Based on end-use, the hospital segment dominated the biological skin substitutes market with a revenue share of 54.97% in 2024. The outpatient facilities segment is expected to witness the fastest CAGR of 8.9% over the forecast period owing to the shorter wait times and more flexible scheduling options
  • North America accounted for the largest revenue share of nearly 41.25% in 2024 owing to the presence of major companies in the region
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Applications
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Biological Skin Substitute Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Prevalence of Chronic Diseases
3.2.1.2. Technological Advancements In Biological Skin Substitutes
3.2.1.3. Rising Geriatric Population
3.2.1.4. Increasing Surgical Procedures
3.2.1.5. Growing Burn And Trauma Cases
3.2.2. Market Restraint Analysis
3.2.2.1. High Cost Of Skin Substitute Products
3.2.2.2. Regulatory Hurdles
3.2.3. Market Opportunity Analysis
3.2.3.1. Growing Demand For Aesthetic Procedures
3.2.3.2. Expansion In Emerging Markets
3.2.4. Market Challenge Analysis
3.2.4.1. Intense Competition
3.3. Biological Skin Substitute Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Biological Skin Substitute Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)
4.1. Definition and Scope
4.2. Type Market Share Analysis, 2024 & 2030
4.3. Global Biological Skin Substitute Market, by Type, 2018 to 2030
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.4.1. Human Donor Tissue -derived Products
4.4.1.1. Human Donor Tissue-derived Products, 2018 - 2030 (USD Million)
4.4.2. Acellular Animal-derived Products
4.4.2.1. Acellular Animal-derived Products, 2018 - 2030 (USD Million)
Chapter 5. Biological Skin Substitute Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)
5.1. Definition and Scope
5.2. Application Market Share Analysis, 2024 & 2030
5.3. Global Biological Skin Substitute Market, by Application, 2018 to 2030
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.4.1. Acute Wounds
5.4.1.1. Acute Wounds market, 2018 - 2030 (USD Million)
5.4.2. Chronic Wounds
5.4.2.1. Chronic Wounds market, 2018 - 2030 (USD Million)
Chapter 6. Biological Skin Substitute Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)
6.1. Definition and Scope
6.2. End Use Market Share Analysis, 2024 & 2030
6.3. Global Biological Skin Substitute Market, by End Use, 2018 to 2030
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.4.1. Hospitals
6.4.1.1. Hospitals market, 2018 - 2030 (USD Million)
6.4.2. Outpatient facilities
6.4.2.1. Outpatient facilities market, 2018 - 2030 (USD Million)
6.4.3. Research and manufacturing
6.4.3.1. Research and manufacturing market, 2018 - 2030 (USD Million)
Chapter 7. Biological Skin Substitute Market: Regional Estimates & Trend Analysis
7.1. Regional Dashboard
7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2024
8.4. Key Company Profiles
8.4.1. Organogenesis Inc.
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Integra LifeSciences Corporation
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Smith+Nephew
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Tissue Regenix
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. MIMEDX Group, Inc.
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Essity Aktiebolag (publ))( Essity Health & Medical)
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Stryker
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Vericel Corporation
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. 3M
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. BioTissue
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings